Hanne L. Haahr
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec.
Journal: Clinical pharmacokinetics
Published: February 13, 2024
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: March 28, 2023
Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus.
Journal: Clinical drug investigation
Published: December 22, 2022
Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Journal: Diabetologia
Published: November 28, 2022
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing.
Journal: BMJ open diabetes research & care
Published: March 30, 2021
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology.
Journal: Trends in pharmacological sciences
Published: March 11, 2021
Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis.
Journal: Diabetes care
Published: June 18, 2020
The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.
Journal: Pediatric diabetes
Published: December 10, 2019
Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.
Journal: Clinical pharmacokinetics
Published: November 01, 2019
Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
Journal: Diabetes, obesity & metabolism
Published: April 08, 2019
Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
Journal: Clinical pharmacokinetics
Published: November 08, 2018
Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Journal: Diabetes, obesity & metabolism
Published: January 09, 2018
Last Updated: 09/26/2026